Clinical Trial

Dose De-escalation in Prostate Radiotherapy Using the MRL

Study acronym: DESTINATION
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 19, 2024 (before its estimated March 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this feasibility study is to learn about dose de-escalation in the treatment of men with intermediate risk prostate cancer. The main question it aims to answer is the technical feasibility of treating prostate cancer with toxicity-minimising radiotherapy on an Magnetic Resonance Linear Accelerator (MR-linac). It will also examine gastrointestinal and genitourinary toxicity in the acute and late setting post radiotherapy as well as Prostate-Specific antigen (PSA) control up until 2 years post treatment. Participants will be treated with radiotherapy to the prostate with which will be given in 30Gy in 5 fractions to the whole prostate and 45Gy in 5 fractions to the dominant lesion.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-01-23; most recent amendment 2024-04-18.
Status change: Not Yet Recruiting → Recruiting 2023-09-07
Trial Details
NCT Number NCT05709496
Lead Sponsor Royal Marsden NHS Foundation Trust
Conditions Prostate Adenocarcinoma
Enrollment 20 participants
Start Date 2023-03-01
Primary Completion 2025-03-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-04-19